Entera Bio Stock (NASDAQ:ENTX)

Forecast Ownership Financials Chart

Previous Close

$1.17

52W Range

$0.91 - $3.22

50D Avg

$1.21

200D Avg

$1.72

Market Cap

$57.18M

Avg Vol (3M)

$156.85K

Beta

1.49

Div Yield

ENTX Company Profile

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 28, 2018

Website

ENTX Performance

ENTX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$42.00K	$181.00K	-
Operating Income	$-11.53M	$-9.59M	$-8.94M
Net Income	$-11.44M	$-9.54M	$-8.89M
EBITDA	$-11.50M	$-9.54M	$-8.80M
Basic EPS	$-0.25	$-0.25	$-0.31
Diluted EPS	$-0.25	$-0.25	$-0.31

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 22May 18, 22 | 8:00 AM

Q4 21Mar 08, 22 | 8:30 AM

Q2 21Aug 16, 21 | 8:30 AM

Peer Comparison

Ticker	Company
IRD	Opus Genetics, Inc.
ANIX	Anixa Biosciences, Inc.
SPRO	Spero Therapeutics, Inc.
AGEN	Agenus Inc.
SEER	Seer, Inc.
HURA	TuHURA Biosciences, Inc.
INO	Inovio Pharmaceuticals, Inc.
VTGN	VistaGen Therapeutics, Inc.
MCRB	Seres Therapeutics, Inc.
ABOS	Acumen Pharmaceuticals, Inc.